Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naïve or experienced patients | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naïve or experienced patients

Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naïve or experienced patients. Am J Gastroenterol. 2017;112(12):1824-1831.

Publication Type:

Journal Article

Authors:

Nguyen, MH; Trinh, H; Do, S; Nguyen, T; Nguyen, P; Henry, L

Source:

Am J Gastroenterol, Volume 112, Issue 12, p.1824-1831 (2017)

Cited On:

Treatment-Naive Genotype 5 or 6

Export Citation:

RIS Format

Top